PHARMACEUTICAL EXECUTIVE NEWSLETTER

In this ISSUE

UK Biopharma: Life After Brexit

An EU Referendum on Drug Pricing?

EMA Develops Strategy on Adaptive Pathways

Regulatory Affairs

“Drug Transparency”: Each Bill Needs Careful Evaluation

Could the new Vermont Drug Transparency law “lead the US Pharmaceutical industry to an awful end”? Tom Norton reports.
... /Read more/

Watch this brief video to learn how emerging technologies and virtual engagements like teledetailing and telepromotions can help you succeed in the evolving model for prescriber engagement.

Learn more

Regulatory Affairs

FDA, Industry Seek Speedy Congressional Approval of New User Fee Plan

Stakeholders are looking to move up the Prescription Drug User Fee Act timeframe to gain Congressional action before the Obama administration steps down.
... /Read more/

Regultory Affairs

The 2016 Cancer Drugs Fund in England

A ‘new’ version of the English Cancer Drugs Fund (CDF) has come into force. Leela Barham reports.
... /Read more/

Opinion

Food and Pharma: The Broadening Reach of Regulators

The lines between the pharma and food industries are blurring, presenting partnering opportunities for life sciences firms — if they understand the regulatory differences, writes Peter Muller.
... /Read more/

Calendar

/ MES 2016 /

/ Patient Journey Mapping - From Diagnosis to Treatment /

/ 10th Annual Forum on Transparency & Aggregate Spend /

/ Partnering with IDNs BioPharma Strategy Summit /

/ Reimbursement and Access 2016 /

/ 340B Manufacturer Summit /

Technology

The Answer is Video. Now What Was the Question?

Media and marketing companies are looking to online video to rescue shrinking advertising rates and capture coveted social traffic. Peter Houston reports.
... /Read more/

update my profile / advertise with us / print & digital subscribe / visit pharmexec.com